Aurobindo Pharma gets USFDA approval for Perampanel tablets
In short
Aurobindo Pharma has got final USFDA approval for Perampanel tablets. The company plans to launch the product in Q3 FY27. The report says the US market for the product is estimated at $67 million, based on IQVIA MAT.
This matters because it could add a new product to Aurobindo Pharma’s US business. The report does not say how much revenue the tablet may bring or when the launch will happen exactly.
What the reporting says
Aurobindo Pharma has received USFDA final approval for Perampanel tablets, according to a publisher-supplied market summary. The product is set to launch in Q3 FY27, and the reported estimated US market size is $67 million based on IQVIA MAT. The reporting does not state the approval date, pricing, or expected sales impact.
Why it matters
Aurobindo Pharma received final USFDA approval for Perampanel tablets, with a launch planned in Q3 FY27. The publisher-supplied summary says the product has an estimated US market size of $67 million, based on IQVIA MAT. The approval is a positive development for the drugmaker’s pipeline, but the reporting does not state launch pricing, volume expectations, or exact timing.